vs
KEY TRONIC CORP（KTCC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是KEY TRONIC CORP的1.3倍（$127.1M vs $96.3M），再鼎医药同比增速更快（17.1% vs -15.4%），KEY TRONIC CORP自由现金流更多（$3.1M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -17.8%）
Key Tronic成立于1969年，最初主营键盘、鼠标等输入设备，目前专注于印刷电路板组装与成品整机组装业务，是美国规模前十的电子制造服务代工厂，可为各类消费家电及电子产品提供完整的产品设计与组装代工服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
KTCC vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.3倍
$96.3M
营收增速更快
ZLAB
高出32.5%
-15.4%
自由现金流更多
KTCC
多$29.8M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-17.8%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $96.3M | $127.1M |
| 净利润 | $-8.6M | — |
| 毛利率 | 0.6% | 51.0% |
| 营业利润率 | -10.7% | -54.6% |
| 净利率 | -8.9% | — |
| 营收同比 | -15.4% | 17.1% |
| 净利润同比 | -74.4% | — |
| 每股收益（稀释后） | $-0.79 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KTCCZLAB
| Q4 25 | $96.3M | $127.1M | ||
| Q3 25 | $98.8M | $115.4M | ||
| Q2 25 | $110.5M | $109.1M | ||
| Q1 25 | $112.0M | $105.7M | ||
| Q4 24 | $113.9M | $108.5M | ||
| Q3 24 | $131.6M | $101.8M | ||
| Q2 24 | $126.6M | $100.1M | ||
| Q1 24 | $142.4M | $87.1M |
净利润KTCCZLAB
| Q4 25 | $-8.6M | — | ||
| Q3 25 | $-2.3M | $-36.0M | ||
| Q2 25 | $-3.9M | $-40.7M | ||
| Q1 25 | $-604.0K | $-48.4M | ||
| Q4 24 | $-4.9M | — | ||
| Q3 24 | $1.1M | $-41.7M | ||
| Q2 24 | $-2.0M | $-80.3M | ||
| Q1 24 | $-2.2M | $-53.5M |
毛利率KTCCZLAB
| Q4 25 | 0.6% | 51.0% | ||
| Q3 25 | 8.4% | 59.5% | ||
| Q2 25 | 6.2% | 60.6% | ||
| Q1 25 | 7.7% | 63.6% | ||
| Q4 24 | 6.8% | 61.5% | ||
| Q3 24 | 10.1% | 64.1% | ||
| Q2 24 | 7.2% | 64.9% | ||
| Q1 24 | 5.7% | 61.4% |
营业利润率KTCCZLAB
| Q4 25 | -10.7% | -54.6% | ||
| Q3 25 | -0.6% | -42.3% | ||
| Q2 25 | -2.1% | -50.3% | ||
| Q1 25 | -0.4% | -53.3% | ||
| Q4 24 | -1.0% | -62.6% | ||
| Q3 24 | 3.4% | -66.6% | ||
| Q2 24 | 0.1% | -76.0% | ||
| Q1 24 | -0.4% | -80.7% |
净利率KTCCZLAB
| Q4 25 | -8.9% | — | ||
| Q3 25 | -2.3% | -31.2% | ||
| Q2 25 | -3.6% | -37.3% | ||
| Q1 25 | -0.5% | -45.8% | ||
| Q4 24 | -4.3% | — | ||
| Q3 24 | 0.9% | -40.9% | ||
| Q2 24 | -1.6% | -80.2% | ||
| Q1 24 | -1.6% | -61.4% |
每股收益（稀释后）KTCCZLAB
| Q4 25 | $-0.79 | $-0.05 | ||
| Q3 25 | $-0.21 | $-0.03 | ||
| Q2 25 | $-0.35 | $-0.04 | ||
| Q1 25 | $-0.06 | $-0.04 | ||
| Q4 24 | $-0.46 | $-0.09 | ||
| Q3 24 | $0.10 | $-0.04 | ||
| Q2 24 | $-0.18 | $-0.08 | ||
| Q1 24 | $-0.21 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $788.0K | $689.6M |
| 总债务越低越好 | $97.7M | — |
| 股东权益账面价值 | $106.2M | $715.5M |
| 总资产 | $325.3M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.92× | — |
8季度趋势，按日历期对齐
现金及短期投资KTCCZLAB
| Q4 25 | $788.0K | $689.6M | ||
| Q3 25 | $1.1M | $717.2M | ||
| Q2 25 | $1.4M | $732.2M | ||
| Q1 25 | $2.5M | $757.3M | ||
| Q4 24 | $4.2M | $779.7M | ||
| Q3 24 | $6.6M | $616.1M | ||
| Q2 24 | $4.8M | $630.0M | ||
| Q1 24 | $5.3M | $650.8M |
总债务KTCCZLAB
| Q4 25 | $97.7M | — | ||
| Q3 25 | $100.8M | — | ||
| Q2 25 | $105.2M | — | ||
| Q1 25 | $113.6M | — | ||
| Q4 24 | $111.1M | — | ||
| Q3 24 | $112.7M | — | ||
| Q2 24 | $119.5M | — | ||
| Q1 24 | $125.3M | — |
股东权益KTCCZLAB
| Q4 25 | $106.2M | $715.5M | ||
| Q3 25 | $114.8M | $759.9M | ||
| Q2 25 | $117.1M | $791.7M | ||
| Q1 25 | $119.6M | $810.8M | ||
| Q4 24 | $119.5M | $840.9M | ||
| Q3 24 | $124.3M | $667.7M | ||
| Q2 24 | $124.0M | $704.2M | ||
| Q1 24 | $130.1M | $762.2M |
总资产KTCCZLAB
| Q4 25 | $325.3M | $1.2B | ||
| Q3 25 | $324.6M | $1.2B | ||
| Q2 25 | $315.9M | $1.2B | ||
| Q1 25 | $328.6M | $1.2B | ||
| Q4 24 | $327.8M | $1.2B | ||
| Q3 24 | $355.9M | $985.3M | ||
| Q2 24 | $355.3M | $987.4M | ||
| Q1 24 | $370.1M | $988.4M |
负债/权益比KTCCZLAB
| Q4 25 | 0.92× | — | ||
| Q3 25 | 0.88× | — | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | 0.95× | — | ||
| Q4 24 | 0.93× | — | ||
| Q3 24 | 0.91× | — | ||
| Q2 24 | 0.96× | — | ||
| Q1 24 | 0.96× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $6.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $3.1M | $-26.7M |
| 自由现金流率自由现金流/营收 | 3.2% | -21.0% |
| 资本支出强度资本支出/营收 | 3.4% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $11.6M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流KTCCZLAB
| Q4 25 | $6.4M | $-26.0M | ||
| Q3 25 | $7.6M | $-32.0M | ||
| Q2 25 | $8.8M | $-31.0M | ||
| Q1 25 | $-1.4M | $-61.7M | ||
| Q4 24 | $1.6M | $-55.8M | ||
| Q3 24 | $9.9M | $-26.8M | ||
| Q2 24 | $7.7M | $-42.2M | ||
| Q1 24 | $-3.0M | $-90.1M |
自由现金流KTCCZLAB
| Q4 25 | $3.1M | $-26.7M | ||
| Q3 25 | $4.4M | $-35.0M | ||
| Q2 25 | $7.7M | $-33.9M | ||
| Q1 25 | $-3.6M | $-63.2M | ||
| Q4 24 | $1.1M | $-58.4M | ||
| Q3 24 | $9.6M | $-28.2M | ||
| Q2 24 | $7.1M | $-42.9M | ||
| Q1 24 | $-3.8M | $-91.1M |
自由现金流率KTCCZLAB
| Q4 25 | 3.2% | -21.0% | ||
| Q3 25 | 4.5% | -30.4% | ||
| Q2 25 | 7.0% | -31.1% | ||
| Q1 25 | -3.2% | -59.9% | ||
| Q4 24 | 1.0% | -53.8% | ||
| Q3 24 | 7.3% | -27.7% | ||
| Q2 24 | 5.6% | -42.9% | ||
| Q1 24 | -2.7% | -104.5% |
资本支出强度KTCCZLAB
| Q4 25 | 3.4% | 0.5% | ||
| Q3 25 | 3.2% | 2.6% | ||
| Q2 25 | 1.0% | 2.6% | ||
| Q1 25 | 2.0% | 1.5% | ||
| Q4 24 | 0.4% | 2.4% | ||
| Q3 24 | 0.3% | 1.3% | ||
| Q2 24 | 0.4% | 0.7% | ||
| Q1 24 | 0.6% | 1.1% |
现金转化率KTCCZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.85× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KTCC
| Transferred Over Time | $91.3M | 95% |
| Transferred At Point In Time | $5.0M | 5% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
